Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2025 08:00 ET | Source: UroGen Pharma Ltd.

UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025

PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...
October 27, 2025 08:00 ET | Source: UroGen Pharma Ltd.

Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026

CMS has issued a permanent J Code for ZUSDURI effective January 1, 2026
October 02, 2025 08:00 ET | Source: UroGen Pharma Ltd.

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer

Reviews in Urology literature review of ZUSDURI (UNG-102) clinical trial program including ENVISION, OPTIMA II and the ATLAS clinical trials
August 05, 2025 08:00 ET | Source: UroGen Pharma Ltd.

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

24-month Duration of Response (DOR) of 72.2% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) PRINCETON, N.J., Aug. 05, 2025 (GLOBE...
July 29, 2025 08:00 ET | Source: UroGen Pharma Ltd.

UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025

Conference Call and Webcast Scheduled for Thursday, August 7th, 2025, at 10:00 AM ET PRINCETON, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company...
July 21, 2025 08:00 ET | Source: UroGen Pharma Ltd.

UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Findings published in the journal of Clinical Genitourinary Cancer show patients remained event-free for a median of two years after achieving complete response with ZUSDURI (mitomycin) intravesical...